US OptionsDetailed Quotes
NKTX241220C7500
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV216.46%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma15.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Nkarta Stock Discussion
Sign in to post a comment
$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
30
31
$Nkarta (NKTX.US)$
Nkarta | SC 13G: Statement of acquisition of beneficial ownership by individuals-Kenneth Griffin(5.4%),Citadel Advisors LLC(4.5%), etc.
Nkarta | SC 13G: Statement of acquisition of beneficial ownership by individuals-Kenneth Griffin(5.4%),Citadel Advisors LLC(4.5%), etc.
$Nkarta (NKTX.US)$
morning star? bottom now with big vol. buy now?
morning star? bottom now with big vol. buy now?
1
1
$Nkarta (NKTX.US)$
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in my...
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in my...
1
1
$Nkarta (NKTX.US)$ Reuters· 2 mins ago
Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
$Nkarta (NKTX.US)$
boom boom boom boom 💥 getting richer from my room 🤣
$Nkarta (NKTX.US)$
$Nkarta (NKTX.US)$
boom boom boom boom 💥 getting richer from my room 🤣
$Nkarta (NKTX.US)$
$Nkarta (NKTX.US)$
Unsupported feature.
Please use the mobile app.
7
1
$Nkarta (NKTX.US)$
I don't know why I didn't share it in my previous post or why I just thought to share it now 🤷🏽 but here we go. this is what I shared with the group.
I know i said not to buy ibrx because it was too volatile. I've changed my tune because of my biopharma outlook.... want it's twin?
cancer killing cell developer, starting with leukemia! buy rating at 17 (i think it pops to 23, but 19 is the full extension) 👌
see that daily turnaround? that's a bottom
see the accumulation at th...
I don't know why I didn't share it in my previous post or why I just thought to share it now 🤷🏽 but here we go. this is what I shared with the group.
I know i said not to buy ibrx because it was too volatile. I've changed my tune because of my biopharma outlook.... want it's twin?
cancer killing cell developer, starting with leukemia! buy rating at 17 (i think it pops to 23, but 19 is the full extension) 👌
see that daily turnaround? that's a bottom
see the accumulation at th...
Unsupported feature.
Please use the mobile app.
6
3
$Nkarta (NKTX.US)$
I shared this with my group. I like cancer treatment biostocks 😁
$Nkarta (NKTX.US)$
I shared this with my group. I like cancer treatment biostocks 😁
$Nkarta (NKTX.US)$
Unsupported feature.
Please use the mobile app.
2
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
?
$Immuneering (IMRX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$ $S&P 500 Index (.SPX.US)$ $BioAtla (BCAB.US)$ $Gilead Sciences (GILD.US)$ $Affimed NV (AFMD.US)$ $Instil Bio (TIL.US)$ $Nkarta (NKTX.US)$
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
10
1
No comment yet
HannChau : any thought on BCTX?
Jaguar8 OP HannChau : I’m hoping it will recover too since it closed its offering today
HannChau Jaguar8 OP : haha, i went in again. I think it will go back to 1 soon![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
S2ET0 HannChau : 我還在1.04![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Jaguar8 OP HannChau : I’ll just re-enter PM hoping no offering is announce over the weekend
View more comments...